Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.92 +1.13%

+$0.32 today

Market cap
$148.08M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.21M

Average 0.28M

STRO Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Sutro Biopharma, Inc.NASDAQ: STRO

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -203.9%

Operating margin was -203.9% in Q1 FY2026, up 189.9 pp from a year earlier. On a trailing-twelve-month basis it was -115.5%, up 261.4 pp year over year. Over 3 fiscal years it widened by 87.9 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 9 analysts of -74.2% for the fiscal year ending Dec 2026, up from -102.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-203.9%+85.1 pp QoQ
Last fiscal yearDec 2025
-102.4%+281.9 pp YoY
LTMMar 2026
-115.5%+261.4 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+189.9 pp-216.5 pp-406.3 pp
1 year+281.9 pp+28.2 pp-253.7 pp
3 years+87.9 pp-11.9 pp-99.7 pp
5 years+77.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-102.4%
Year-over-year change
+281.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How STRO compares with its peers on the latest reported figures

  • STRO's LTM Mar 2026 operating margin of -115.5% is the 2nd highest of the 5 companies compared; the peer median is -48003.5%.
  • Its year-over-year change of +261.4 pp is the highest of 5, against a peer median of -47147.2 pp.
  • Over three fiscal years its change of +87.9 pp compares with a peer median of +5396.6 pp.
STRO Competitors Peer median
Operating Margin for STRO and competitors
Company Period LTM level YoY 3-year change
DTILPrecision BioSciences, Inc.LTM Mar 2026-86.8% -0.6 pp+96.1 pp
STROSutro Biopharma, Inc.LTM Mar 2026-115.5% +261.4 pp+87.9 pp
STTKShattuck Labs, Inc.LTM Mar 2026-5266.4% -3640.0 pp+10697.2 pp
CNTBConnect Biopharma Holdings LimitedFY2025-90740.6% -90654.4 pp—
IFRXInflaRx N.V.LTM Mar 2026-144445.0% -103193.3 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
KLRSKalaris Therapeutics IncFY2025— ——
GUTSFractyl Health, Inc. Common StockFY2025— ——
Peer median (excluding STRO) -48003.5%-47147.2 pp+5396.6 pp

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.